Oslo, Norway, May 14, 2024 - The Ordinary General Meeting of Lytix Biopharma AS
("Lytix" or the "Company") was held on May 14, 2024. All proposed resolutions on
the agenda were approved.

Minutes of the meeting are attached hereto.

The minutes and all documents relevant for the annual general meeting are
available on the Company's website.

For more information, please contact:
Gjest Breistein, CFO 
+47 952 60 512
gjest.breistein@lytixbiopharma.com

About Lytix
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly novel technology based on world leading research in host-defense
peptide-derived molecules. Lytix Biopharma's lead product, LTX-315, is a
first-in-class oncolytic molecule representing a new principle to boost
anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work
in many different cancer indications and treatment settings, both as mono- and
combination therapy.